Literature DB >> 3473311

McArdle's disease with myoadenylate deaminase deficiency: observations in a combined enzyme deficiency.

S L Heller, K K Kaiser, G J Planer, J M Hagberg, M H Brooke.   

Abstract

Exercise and work potential of a patient with coexistent myophosphorylase and myoadenylate deaminase (AMPDA) deficiency was compared with that of three patients with myophosphorylase deficiency alone. The patient with the combined defect failed to produce an abnormal rise in serum ammonia or hypoxanthine as seen in the other patients after forearm exercise. Maximum oxygen consumption and work rates during cycle ergometer testing were similar in all patients, but well below controls. The occurrence of two defects involving short-term energy metabolism in muscle presents an opportunity to define further the metabolic role of AMPDA.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3473311     DOI: 10.1212/wnl.37.6.1039

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  4 in total

1.  Muscle metabolism and red cell ATP/ADP concentration during bicycle ergometer in patients with AMPD-deficiency.

Authors:  D R Wagner; J Felbel; U Gresser; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-04-04

2.  McArdle's disease: successful symptomatic therapy by high dose oral administration of ribose.

Authors:  D R Wagner; N Zöllner
Journal:  Klin Wochenschr       Date:  1991-01-22

3.  Molecular basis of AMP deaminase deficiency in skeletal muscle.

Authors:  T Morisaki; M Gross; H Morisaki; D Pongratz; N Zöllner; E W Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

4.  Diagnostic Algorithm for Glycogenoses and Myoadenylate Deaminase Deficiency Based on Exercise Testing Parameters: A Prospective Study.

Authors:  Fabrice Rannou; Arnaud Uguen; Virginie Scotet; Cédric Le Maréchal; Odile Rigal; Pascale Marcorelles; Eric Gobin; Jean-Luc Carré; Fabien Zagnoli; Marie-Agnès Giroux-Metges
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.